14892-97-8
14892-97-8 結(jié)構(gòu)式
基本信息
SCR7 PYRAZINE產(chǎn)
6,7-二苯基-2-磺?；?1H-蝶啶-4-酮
2,3-二氫-6,7-二苯基-2-硫代-4(1H)-蝶啶酮
6,7-二苯基-2-硫氧基-2,3-二氫蝶呤-4(1H)-酮
6,7-diphenyL
SCR7 pyrazine
SCR7
SCR-7
SCR 7.
6,7-Diphenyl-2-thiolumazine
6,7-Diphenyl-2-sulfanylpteridin-4-ol
"6,7-diphenyl-2-sulfanylidene-1H-pteridin-4-one
2,3-Dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone
6,7-Diphenyl-2-thioxo-2,3-dihydropteridin-4(1H)-one
6,7-Diphenyl-2-thioxo-2,3-dihydropteridin-4(8H)-one
物理化學性質(zhì)
制備方法
100-52-7
1004-76-8
14892-97-8
方法A: 將苯甲醛(466 mg, 4.4 mmol)溶于DMF(1.5 mL)和乙酸(0.5 mL)中，所得溶液緩慢加入至固體4,5-二氨基-6-羥基-2-巰基嘧啶(316 mg, 2.0 mmol)中。反應(yīng)混合物于回流條件下加熱3小時，隨后冷卻至室溫，并緩慢加入10 mL冰水。析出的黃色固體經(jīng)真空過濾收集，自然干燥。將干燥后的固體溶于60 mL氯仿中，過濾氯仿溶液以去除不溶物。將全部氯仿溶液上樣至預(yù)先以二氯甲烷填充的硅膠柱上，以二氯甲烷:乙酸乙酯(2:1, v/v)為洗脫劑進行柱層析，收集第一個黃色條帶。減壓濃縮洗脫液，得到目標產(chǎn)物257 mg(0.77 mmol, 收率39%)。產(chǎn)物表征數(shù)據(jù)如下: 1H NMR (DMSO-d6) δ 13.42 (br.s, 1H), 12.82 (br.s, 1H), 7.43-7.34 (m, 10H); 13C NMR (DMSO-d6) δ 175.7, 158.5, 155.9, 149.1, 147.0, 137.7, 137.1, 129.8 (CH), 129.7 (CH), 129.5 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 127.2; HRMS (ESI) m/z calcd for C18H13N4OS [M+H]+ 333.0810, found 333.0802; IR (Nujol) νmax 3407 (br), 1698, 1633, 1552, 1126, 722, 695, 665 cm-1; mp 200-203 °C (dec.); UV/Vis λmax 380 nm (ε = 12,000 M-1 cm-1).
參考文獻：
[1] Tetrahedron Letters, 2016, vol. 57, # 29, p. 3204 - 3207
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/05/22 | HY-107845 | SCR7吡嗪 SCR7 pyrazine | 14892-97-8 | 1 mg | 386元 |
| 2025/05/22 | HY-107845 | SCR7吡嗪 SCR7 pyrazine | 14892-97-8 | 5mg | 850元 |
| 2025/05/22 | HY-107845 | SCR7吡嗪 SCR7 pyrazine | 14892-97-8 | 10mM * 1mLin DMSO | 935元 |
常見問題列表
DNA Ligase IV
CRISPR/Cas9
SCR7 pyrazine (20-100 μM; 24 hours; MCF7 cells) treatment interferes with NHEJ in cells, leading to accumulation of unrepaired double-strand breaks (DSBs).
SCR7 pyrazine treatment shows a dose-dependent decrease in cell proliferation with IC
50
values of 40 μM, 34 μM, 44 μM, 8.5 μM, 120 μM, 10 μM and 50 μM for MCF7, A549, HeLa, T47D, A2780, HT1080 and Nalm6 cells, respectively.
In MCF7 cells, SCR7 pyrazine (20, 40 μM) treatment increases phosphorylation of ATM and activates p53, decreases MDM2, BCL2, resulting in activation of proapoptotic proteins, PUMA and BAX. And the shorter fragments of MCL1, PARP1, Caspase 3, and Caspase 9 cleavage are upregulated in a dose-dependent manner.
Western Blot Analysis
| Cell Line: | MCF7 cells |
| Concentration: | 20 μM, 40 μM, 100 μM |
| Incubation Time: | 24 hours |
| Result: | Showed an increase in levels of gH2AX foci and protein. |
SCR7 pyrazine (10 mg/kg; intraperitoneal injection; six doses; BALB/c mice) treatment significantly reduces breast adenocarcinoma-induced tumor and increases lifespan.
| Animal Model: | BALB/c mice injected with breast adenocarcinoma cells |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; on alternate days (0, 2, 4, 6, 8, and 10) |
| Result: | Significantly reduced breast adenocarcinoma-induced tumor and increased lifespan. |